Soulé JC - Search Results

1

Association between entero-hepatic Helicobacter species and Crohn's disease: a prospective cross-sectional study.

Laharie D, Asencio C, Asselineau J, Bulois P, Bourreille A, Moreau J, Bonjean P, Lamarque D, Pariente A, Soulé JC, Charachon A, Coffin B, Perez P, Mégraud F, Zerbib F. Laharie D, et al. Among authors: soule jc. Aliment Pharmacol Ther. 2009 Aug;30(3):283-93. doi: 10.1111/j.1365-2036.2009.04034.x. Epub 2009 May 5. Aliment Pharmacol Ther. 2009. PMID: 19438427

2

Infliximab treatment for symptomatic Crohn's disease strictures.

Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC. Pelletier AL, et al. Among authors: soule jc. Aliment Pharmacol Ther. 2009 Feb 1;29(3):279-85. doi: 10.1111/j.1365-2036.2008.03887.x. Epub 2008 Nov 8. Aliment Pharmacol Ther. 2009. PMID: 19035967

3

[Gastroesophageal reflux (II). Major medical therapeutics: efficacy and risks].

Soulé JC. Soulé JC. Presse Med. 1997 Sep 13;26(26):1257-63. Presse Med. 1997. PMID: 9380633 Review. French.

4

[Prevention of duodenal ulcer recurrence. A new prospect].

Soulé JC. Soulé JC. Presse Med. 1991 Mar 16;20(10):465-70. Presse Med. 1991. PMID: 1673786 Review. French.

5

[Gastroesophageal reflux (II). Surgical interventions: results and indications].

Soulé JC. Soulé JC. Presse Med. 1997 Sep 13;26(26):1265-9. Presse Med. 1997. PMID: 9380634 Review. French.

6

High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease.

Beaugerie L, Carrat F, Nahon S, Zeitoun JD, Sabaté JM, Peyrin-Biroulet L, Colombel JF, Allez M, Fléjou JF, Kirchgesner J, Svrcek M; Cancers et Surrisque Associé aux Maladies Inflammatoires Intestinales En France Study Group. Beaugerie L, et al. Clin Gastroenterol Hepatol. 2018 Jun;16(6):892-899.e2. doi: 10.1016/j.cgh.2017.11.041. Epub 2017 Dec 2. Clin Gastroenterol Hepatol. 2018. PMID: 29199142

7

The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease.

Carrat F, Seksik P, Colombel JF, Peyrin-Biroulet L, Beaugerie L; CESAME Study Group. Carrat F, et al. Aliment Pharmacol Ther. 2017 Feb;45(4):533-541. doi: 10.1111/apt.13897. Epub 2016 Dec 19. Aliment Pharmacol Ther. 2017. PMID: 27995656 Free article.

8

Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

Bourrier A, Carrat F, Colombel JF, Bouvier AM, Abitbol V, Marteau P, Cosnes J, Simon T, Peyrin-Biroulet L, Beaugerie L; CESAME study group. Bourrier A, et al. Aliment Pharmacol Ther. 2016 Jan;43(2):252-61. doi: 10.1111/apt.13466. Epub 2015 Nov 9. Aliment Pharmacol Ther. 2016. PMID: 26549003

9

Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer.

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L; CESAME Study Group. Beaugerie L, et al. Gut. 2014 Sep;63(9):1416-23. doi: 10.1136/gutjnl-2013-305763. Epub 2013 Oct 25. Gut. 2014. PMID: 24162591

10

Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease.

Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas JL, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N; CESAME Study Group. Sokol H, et al. Inflamm Bowel Dis. 2012 Nov;18(11):2063-71. doi: 10.1002/ibd.22889. Epub 2012 Jan 23. Inflamm Bowel Dis. 2012. PMID: 22271569

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

112 results

Search Page

Filters